Unknown

Dataset Information

0

Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective.


ABSTRACT: Aim: The cost-effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Materials & methods: Cost-effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Results: Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost-effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. Conclusion: OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.

SUBMITTER: Murray B 

PROVIDER: S-EPMC10288955 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective.

Murray Brian B   Miles-Thomas Jennifer J   Park Amy J AJ   Nguyen Victor B VB   Tung Amy A   Gillard Patrick P   Lalla Anjana A   Nitti Victor W VW   Chermansky Christopher J CJ  

Journal of comparative effectiveness research 20230119 2


<b>Aim:</b> The cost-effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. <b>Materials & methods:</b> Cost-effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were  ...[more]

Similar Datasets

| S-EPMC10637034 | biostudies-literature
| S-EPMC5696295 | biostudies-literature
| S-EPMC4689973 | biostudies-literature
| S-EPMC5434500 | biostudies-literature
| S-EPMC4675184 | biostudies-literature
| S-EPMC11794756 | biostudies-literature
| S-EPMC8355577 | biostudies-literature
| S-EPMC7018934 | biostudies-literature
| S-EPMC4030445 | biostudies-literature
| S-EPMC11787189 | biostudies-literature